Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:54 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC)
NCT03071094 · Transgene · PHASE1/PHASE2 · terminated · last registry update 2021-11-19 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The decision was taken to stop prematurely the trial due to the failure of Pexa-Vec and nivolumab in their respective pivotal trials (i.e., PHOCUS and CheckMate 459).” | – | Registry record, Transgene |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CSF2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-03-09Results posted on the registry: GlaxoSmithKline, Otilimab + Placebo 1 (NCT04376684)
- 2022-03-08Results posted on the registry: Izana Bioscience Ltd., Placebo + Namilumab (NCT03622658)
- 2021-12-10Results posted on the registry: Kinevant Sciences GmbH, Gimsilumab + Placebo (NCT04351243)
- 2021-10-26Results posted on the registry: National Cancer Institute (NCI), Durvalumab + Tremelimumab (NCT03206073)
- 2021-01-08Results posted on the registry: Jennerex Biotherapeutics, JX-594 + Irinotecan (NCT01394939)
- 2020-12-16Results posted on the registry: SillaJen, Inc., Pexastimogene Devacirepvec (Pexa Vec) + Sorafenib (NCT02562755)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision